The author of this review concluded that there was no clear evidence to support the choice of hyoscine over glycopyrronium for drying up the secretions that cause the 'death rattle'. A thorough search identified only two relevant studies with conflicting results. The author's interpretation of the evidence was appropriate and the conclusion is likely to be reliable.
Data extraction
The author did not state how the data were extracted for the review, or how many reviewers performed the data extraction. The data extracted were as reported in the original studies, and included the proportion of patients with the outcome of interest and p-values obtained from tests of statistical significance.
Methods of synthesis
How were the studies combined? A narrative synthesis was performed.
How were differences between studies investigated? Differences in study design, population, intervention and outcome measures were discussed in the text and summarised in a table.
Results of the review
Two non-randomised studies with a control group were included. The total number of participants was 265. One study was a two-phase group comparison with 191 participants, while the other was a prospective comparative audit of 74 participants who received the drugs of interest.
Both study reports lacked quantitative data on the drugs actually given (rather than intended). In one included study the participants in each treatment group were in separate palliative care units. The other study was conducted in two phases in the same unit: participants in the first 11-month phase were given hyoscine and those in the second 9-month phase were given glycopyrronium. One study did not report levels of statistical significance for treatment differences.
In the two-phase study, patients treated with hyoscine were significantly more likely to respond to the first drug dose than patients in the glycopyrronium group (56% versus 27%, p=0.002) and significantly less likely to require a second injection (33% versus 50%, p=0.03). There was no significant difference in the proportion of patients in each treatment group who had relief from respiratory secretions at death.
In the audit study, patients treated with hyoscine were less likely to respond after the first drug dose than patients in the glycopyrronium group (35% versus 46%) and less likely to remain settled within three doses (32% versus 49%). Statistical significance was not reported. The number of patients whose secretions were relieved at death for hyoscine compared with glycopyrronium could not be established because glycopyrronium was recommended in both treatment protocols after step three.
Authors' conclusions
There was no clear evidence of a reduction in respiratory symptoms to support the choice of hyoscine over glycopyrronium in terminally ill patients.
CRD commentary
The review addressed a clear question and clearly defined the inclusion criteria. The search to identify relevant studies was thorough and well reported, although one aspect that was not mentioned was the eligibility of foreign language studies. The review was conducted by a single author and did not report methods to minimise bias and errors in the study selection, appraisal or data extraction. Given the evident extensive effort made to identify relevant studies and the precision of the inclusion criteria, on balance it was likely that the most relevant studies were identified. The included studies were well described (as far as the original reports allowed) and appropriately appraised, and a proper narrative synthesis was conducted and clearly reported. The author's conclusion is an appropriate interpretation of the evidence reviewed and is likely to be reliable.
